October 10, 2016 / 11:51 AM / in 9 months

REFILE-BRIEF-Ariad Pharma's Brigatinib's safety profile similar with longer follow-up

1 Min Read

(Adds dropped words "says Brigatinib's" in headline)

Oct 10 (Reuters) - Ariad Pharmaceuticals Inc

* Press release - Ariad presents updated long-term follow-up results from the phase 1/2 trial on investigational drug Brigatinib at 2016 ESMO meeting

* Ariad Pharmaceuticals Inc - safety profile was similar with longer follow-up

* Ariad Pharmaceuticals Inc - in eight Crizotinib-Naive ALK+ NSCLC patients, confirmed ORR was 100% Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below